Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2013-08-15 Regulatory Filings
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Medivir tar strategiskt beslut att fokusera F&U-resurserna inom hepatit C-området på nukleotidbaserade polymerashämmare
Regulatory Filings Classification · 99% confidence The document is a press release dated August 15, 2013, announcing a strategic decision by Medivir AB regarding the focus of its R&D resources within its Hepatitis C projects (specifically discontinuing the NS5A inhibitor project to focus on nucleotide-based polymerase inhibitors). This type of announcement, detailing strategic shifts, project discontinuation, or internal operational decisions that impact future development but are not full financial results (ER) or capital structure changes (CAP), often falls under general corporate news or regulatory updates. Since it is a strategic R&D decision announcement, it is not a standard 10-K, IR, ER, or CT. It is a specific corporate action announcement. Given the options, it is best classified as a general Regulatory Filing (RNS) as it is a formal announcement to the market about a significant internal strategic change, or potentially a general Corporate Governance/Information release, but RNS serves as the best catch-all for non-standard, material corporate news releases that aren't explicitly defined elsewhere. It is not a Director's Dealing (DIRS), Dividend (DIV), or M&A (TAR). Given its nature as a formal press release detailing a strategic pivot, RNS is the most appropriate general regulatory announcement category.
2013-08-15 Swedish
Medivir streamlines operations by divesting Cross Pharma, its parallel import business
M&A Activity Classification · 99% confidence The document is a press release dated June 25, 2013, announcing the divestiture (sale) of a wholly owned subsidiary, Cross Pharma AB, by Medivir AB to MedCap AB's subsidiary. This transaction involves a significant corporate restructuring and change in business focus (divesting a non-core asset to focus on proprietary prescription products). This type of announcement, detailing a major corporate transaction like a sale or acquisition, falls under the category of M&A Activity (TAR). It is not an earnings release (ER), an interim report (IR), or a general regulatory filing (RNS), as it specifically details a merger/acquisition/divestiture event.
2013-06-25 English
Medivir renodlar verksamheten och avyttrar parallellimportverksamheten Cross Pharma
M&A Activity Classification · 99% confidence The document is a press release dated June 25, 2013, announcing that Medivir AB is selling its subsidiary Cross Pharma AB to Unimedic AB for 125 MSEK. This transaction involves the divestiture of a business unit, which is a significant corporate financing or capital structure change activity. This aligns best with the 'Capital/Financing Update' category (CAP), as it details a major asset sale intended to strengthen the financial position and refocus the company's structure. It is not an earnings release (ER), an interim report (IR), or a standard M&A announcement (TAR), but rather a specific corporate action related to capital structure/financing.
2013-06-25 Swedish
Medivir rekryterar ny chef för den kommersiella verksamheten
Board/Management Information Classification · 98% confidence The document is a press release dated June 14, 2013, announcing the recruitment of a new Executive Vice President Commercial (Henrik Krook) to the management team. This directly concerns a change in senior management personnel. According to the definitions, announcements of changes in the company's board of directors or senior management fall under the 'Board/Management Information' category.
2013-06-14 Swedish
Medivir recruits a new head of Commercial Operations
Board/Management Information Classification · 99% confidence The document is a press release dated June 14, 2013, announcing the recruitment of a new head of Commercial Operations (Henrik Krook) to the executive management team. This announcement details a change in senior management personnel. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The content perfectly matches this description.
2013-06-14 English
Major Shareholding Notification 2013
Major Shareholding Notification Classification · 99% confidence The document explicitly details a change in shareholding percentage for a specific holder ('AFA Försäkring') in the issuer ('Medivir Aktiebolag'). It lists the 'Reason for major shareholding notification' and provides the 'Before the transaction' and 'After the transaction' share quantities and resulting percentages. This structure perfectly matches the definition of a Major Shareholding Notification, which corresponds to the filing code MRQ.
2013-06-12 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.